Discussion
heart failure, diastolic dysfunction, diabetes mellitus
DIASTOLIC DYSFUNCTION, DIABETES MELLITUS, SECONDARY, HEART FAILURE, TYPE 2 DIABETES MELLITUS
The present study investigated the effects of the SGLT2 inhibitor empagliflozin in patients with diastolic dysfunction and type 2 diabetes mellitus. The results indicate a significant improvement in diastolic function as measured by left ventricular The results of the EmDia trial add to the growing body of evidence supporting a positive effect of empagliflozin on cardiovascular health [The transient reduction in systolic and diastolic blood pressure after one week of therapy supports the hypothesis that part, and in particular the early, cardiovascular effects of empagliflozin may be mediated via an improvement in ventricular loading through a reduction in afterload that is likely secondary to the diuretic effects of the drug [The improvement in diastolic function found in the EmDia trial provides new insights relevant in context of the results of the recently published EMPEROR-PRESERVED clinical trial investigating the efficacy and safety of empagliflozin in individuals with heart failure and preserved ejection fraction (defined by a left ventricular ejection fraction > 40%) independent of the presence of diabetes mellitus [